Company intelligence / Profile preview

HCDE

Cambridge, Massachusetts, United Stateshcde-texas.org ↗

Ownership: Private
Development stage: Other

Overview

HC Bioscience developed a protein editing platform based on engineered transfer RNA (tRNA) to overwrite disease-causing mutations at the translational level, aiming to restore functional protein production. The lead program targeting hemophilia A was discontinued after preclinical data revealed challenges with targeted delivery. The company ceased operations in early 2025.

Therapeutic areas: Rare DiseasesHematologyOncology
Modalities: tRNA-based therapyLipid nanoparticle delivery therapySmall molecule (for delivery vehicles)
Industry: Biotech

Beyond the preview

Go deeper on HCDE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCDE.

Explore the full profile